EyePoint reports topline data from LUGANO Phase 3 DURAVYU 2.7mg trial
EyePoint (EYPT) announces topline data from LUGANO, the first of two pivotal Phase 3 trials for DURAVYU™ 2.7mg in wet AMD, with no additional figures provided.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.